Safety and Pharmacokinetics of a Single Oral TPN171H in Healthy Elderly Subjects - Trial NCT06090136
Access comprehensive clinical trial information for NCT06090136 through Pure Global AI's free database. This Phase 1 trial is sponsored by Vigonvita Life Sciences and is currently Completed. The study focuses on Erectile Dysfunction. Target enrollment is 12 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Vigonvita Life Sciences
Timeline & Enrollment
Phase 1
Sep 14, 2020
Jul 22, 2022
Primary Outcome
Adverse events,Pharmacokinetic parameter of TPN171H:Tmax,Pharmacokinetic parameter of TPN171H:Cmax,Pharmacokinetic parameter of TPN171H:T1/2,Pharmacokinetic parameter of TPN171H:AUC0-t,Pharmacokinetic parameter of TPN171H:AUC0-∞,Pharmacokinetic parameter of TPN171H:AUC0-24h,Pharmacokinetic parameter of TPN171H:Ke,Pharmacokinetic parameter of TPN171H:Vd,Pharmacokinetic parameter of TPN171H:MRT,Pharmacokinetic parameter of TPN171H:CL/F,Pharmacokinetic parameter of TPN171H:BRPP
Summary
It is a single-center, open-label, Phase I clinical study evaluating the safety and
 pharmacokinetics of a single oral TPN171H in elderly subjects.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06090136
Non-Device Trial